Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 5/2009

01-05-2009 | ORIGINAL ARTICLE

Irritable Bowel Syndrome and Gastroesophageal Reflux Disease in Primary Care: Is There a Link?

Authors: Ana Ruigómez, Mari-Ann Wallander, Saga Johansson, Luis Alberto García Rodríguez

Published in: Digestive Diseases and Sciences | Issue 5/2009

Login to get access

Abstract

Population-based studies have shown that gastroesophageal reflux disease (GERD) and irritable bowel syndrome (IBS) coexist more commonly than expected by chance. We aimed to investigate the relationship between GERD and IBS in primary care. The General Practice Research Database was used to identify patients with a first diagnosis of GERD (n = 6,421) or IBS (n = 2,932). Patients were followed up for 12 months after diagnosis to investigate the incidence of IBS among GERD patients and GERD among IBS patients. The relative risk (RR) of developing IBS was 3.5 (95% CI: 2.3–5.4) in the GERD cohort compared with the comparison cohort. The RR of developing GERD was 2.8 (95% CI: 1.7–4.9) in the IBS cohort compared with the comparison cohort. A first diagnosis of either IBS or GERD significantly increases the risk of a subsequent diagnosis of the other condition.
Literature
1.
2.
3.
4.
Kennedy TM, Jones RH, Hungin AP, O’Flanagan H, Kelly P. Irritable bowel syndrome, gastro-oesophageal reflux, and bronchial hyper-responsiveness in the general population. Gut. 1998;43:770–774.PubMed
5.
Wang JH, Luo JY, Dong L, Gong J, Tong M. Epidemiology of gastroesophageal reflux disease: a general population-based study in Xi’an of Northwest China. World J Gastroenterol. 2004;10:1647–1651.PubMed
6.
7.
8.
Zagari RM, Pozzato P, Damian S, et al. The epidemiology of irritable bowel syndrome and its relationship with gastroesophageal reflux disease in the general population: results from the Loiano–Monghidoro study. Gastroenterology. 2006;130:S1132.
9.
Jung HK, Halder S, McNally M, et al. Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population. Aliment Pharmacol Ther. 2007;26:453–461.PubMed
10.
11.
12.
Guillemot F, Ducrotte P, Bueno L. Prevalence of functional gastrointestinal disorders in a population of subjects consulting for gastroesophageal reflux disease in general practice. Gastroenterol Clin Biol. 2005;29:243–246. doi:10.​1016/​S0399-8320(05)80756-0.PubMed
13.
Agreus L, Svardsudd K, Talley NJ, Jones MP, Tibblin G. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol. 2001;96:2905–2914.PubMed
14.
15.
16.
Lawson D, Sherman V, Hollowell J. The general practice research database. Q J Med. 1998;91:445–452.
17.
18.
Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991;302:766–768.PubMedCrossRef
19.
20.
21.
Nasseri-Moghaddam S, Razjouyan H, Mamarabadi M, et al. Factors contributing in response of patients with gastroesophageal reflux disease to PPI therapy. Gastroenterology. 2008;134:A323.
22.
23.
Saito YA, Schoenfeld P, Locke GR 3rd. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol. 2002;97:1910–1915.PubMed
24.
25.
26.
27.
28.
Whitehead WE, Crowell MD. Psychologic considerations in the irritable bowel syndrome. Gastroenterol Clin North Am. 1991;20:249–267.PubMed
29.
El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life. Rev Gastroenterol Disord. 2003;3:S3–S11.PubMed
30.
31.
32.
33.
Talley NJ, Boyce PM, Jones M. Predictors of health care seeking for irritable bowel syndrome: a population based study. Gut. 1997;41:394–398.PubMed
34.
35.
36.
37.
Eliakim R, Abulafia O, Sherer DM. Estrogen, progesterone and the gastrointestinal tract. J Reprod Med. 2000;45:781–788.PubMed
38.
Bond EF, Heitkemper MM, Bailey SL. Estrogen suppresses gastric motility response to thyrotropin-releasing hormone and stress in awake rats. Res Nurs Health. 1998;21:221–228. doi :10.1002/(SICI)1098-240X(199806)21:3<221::AID-NUR5>3.0.CO;2-J.PubMedCrossRef
39.
40.
Li TJ, Yu BP, Dong WG, Luo HS, Xu L, Li MQ. Ovarian hormone modulates 5-hydroxytryptamine 3 receptors mRNA expression in rat colon with restraint stress-induced bowel dysfunction. World J Gastroenterol. 2004;10:2723–2726.PubMed
41.
42.
43.
44.
45.
46.
47.
48.
49.
Bijkerk CJ, de Wit NJ, Stalman WA, Knottnerus JA, Hoes AW, Muris JW. Irritable bowel syndrome in primary care: the patients’ and doctors’ views on symptoms, etiology and management. Can J Gastroenterol. 2003;17:363–368. quiz 405–406.PubMed
Metadata
Title
Irritable Bowel Syndrome and Gastroesophageal Reflux Disease in Primary Care: Is There a Link?
Authors
Ana Ruigómez
Mari-Ann Wallander
Saga Johansson
Luis Alberto García Rodríguez
Publication date
01-05-2009
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 5/2009
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-008-0462-0

Other articles of this Issue 5/2009

Digestive Diseases and Sciences 5/2009 Go to the issue

Original Article

Comparative Effects of a High-Amylose Starch and a Fructooligosaccharide on Fecal Bifidobacteria Numbers and Short-Chain Fatty Acids in Pigs Fed Bifidobacterium animalis

Original Article

Taurocholate Potentiates Ethanol-Induced NF-κB Activation and Inhibits Caspase-3 Activity in Cultured Rat Gastric Mucosal Cells

ORIGINAL ARTICLE

Abdominal Surgery Affects Small Bowel Transit Time and Completeness of Capsule Endoscopy

Original Article

Clarifying the Relationship Between ABO/Rhesus Blood Group Antigens and Upper Gastrointestinal Bleeding

ORIGINAL ARTICLE

The Effects of Melatonin on Colonic Transit Time in Normal Controls and IBS Patients

Stanford Multidisciplinary Seminars

Troubles with Stomach Bubbles? Or Not?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits